Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...